Key points are not available for this paper at this time.
Thrombotic microangiopathy (TMA) is a rare but potentially life-threatening complication following autologous stem cell transplantation (ASCT). The incidence is extremely low. Here, we present the case of a 54-year-old male with relapsed diffuse large B-cell lymphoma (DLBCL) who developed TMA within 92 days after ASCT. The patient exhibited signs of hemolysis, thrombocytopenia and rapid renal function deterioration, and necessitating initiation of hemodialysis. Kidney biopsy confirmed TMA and Genetic testing revealed Complement H factor deficiency. Treatment with plasma exchange and corticosteroids resulted in no significant response. The patient was ultimately managed with ravulizumab. Transplant associated TMA (TA-TMA) is a an entity in which TMA occurs following stem cell transplant. This case highlights the importance of considering TMA in the differential diagnosis of renal failure following ASCT and initiating prompt treatment as delayed management can lead to devastating outcomes.
Matarneh et al. (Mon,) studied this question.